Evidence map›Paper›PMID 38019013›Full record

ArticleJournal of virology2023

Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants.

Kan Li, Richard H C Huntwork, Gillian Q Horn, Milite Abraha, Kathryn M Hastie, Haoyang Li, Vamseedhar Rayaprolu, Eduardo Olmedillas, Elizabeth Feeney, Kenneth Cronin and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kan LiCenter for Human Systems Immunology, Duke University, Durham, North Carolina, USA.ORCID 0009-0004-0582-3863
Richard H C HuntworkCenter for Human Systems Immunology, Duke University, Durham, North Carolina, USA.
Gillian Q HornCenter for Human Systems Immunology, Duke University, Durham, North Carolina, USA.
Milite AbrahaCenter for Human Systems Immunology, Duke University, Durham, North Carolina, USA.
Kathryn M HastieCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Haoyang LiCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Vamseedhar RayaproluCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Eduardo OlmedillasCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Elizabeth FeeneyCenter for Human Systems Immunology, Duke University, Durham, North Carolina, USA.
Kenneth CroninDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Sharon L SchendelCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Mark HeiseDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.
Daniel BedingerCarterra Inc., Salt Lake City, Utah, USA.
Melissa D MattocksDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
Ralph S BaricDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0001-6827-8701
S Munir AlamDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Erica Ollmann SaphireCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Georgia D TomarasCenter for Human Systems Immunology, Duke University, Durham, North Carolina, USA.ORCID 0000-0001-8076-1931
S Moses DennisonCenter for Human Systems Immunology, Duke University, Durham, North Carolina, USA.ORCID 0000-0003-1198-9179

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
NIAID NIH HHS U19 AI142790
6 · The paper itself

Abstract

importanceMultiple SARS-CoV-2 variants of concern have emerged and caused a significant number of infections and deaths worldwide. These variants of concern contain mutations that might significantly affect antigen-targeting by antibodies. It is therefore important to further understand how antibody binding and neutralization are affected by the mutations in SARS-CoV-2 variants. We highlighted how antibody epitope specificity can influence antibody binding to SARS-CoV-2 spike protein variants and neutralization of SARS-CoV-2 variants. We showed that weakened spike binding and neutralization of Beta (B.1.351) and Omicron (BA.1) variants compared to wildtype are not universal among the panel of antibodies and identified antibodies of a specific binding footprint exhibiting consistent enhancement of spike binding and retained neutralization to Beta variant. These data and analysis can inform how antigen-targeting by antibodies might evolve during a pandemic and prepare for potential future sarbecovirus outbreaks.

Indexed as

Antibodies, NeutralizingAntibodies, ViralSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19HumansSevere acute respiratory syndrome-related coronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE-2 blockingbinding kineticsbiolayer interferometryCOVID-19epitope binningmonoclonal antibodiesneutralizing antibodiesRBDSARS-CoV-2surface plasmon resonance

Identifiers

PMID38019013
PMCPMC10746274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.